Advertisement
Screener

ENDONOVO THERAPEUTICS, INC. (ENDV) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

1.6 / 5 stars · 18/56 Roast Me

ENDONOVO THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

ENDONOVO THERAPEUTICS, INC. (ENDV) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 1.58% for the 12-month period ending 2018-12-31, per its 10-K filed 2020-05-04.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2020-05-04

  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2017-09-30 was 1.05%, a 101.92% increase year-over-year.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2017-06-30 was 1.05%, a 133.33% increase year-over-year.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2017-03-31 was 0.79%, a 33.90% increase year-over-year.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2016-09-30 was 0.52%.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2018 was 1.58%, a 5.33% increase from fiscal 2017.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2017 was 1.50%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month
2018-12-311.58%
10-K · filed 2020-05-04
2017-12-311.50%
10-K · filed 2019-04-15
2017-09-301.05%
10-Q/A · filed 2017-11-09
1.03%
10-Q/A · filed 2017-11-09
2017-06-301.05%
10-Q · filed 2017-08-10
0.45%
10-Q · filed 2017-08-10
2017-03-310.79%
10-Q · filed 2017-05-12
2016-09-300.52%
10-Q/A · filed 2017-11-09
0.45%
10-Q/A · filed 2017-11-09
2016-06-300.45%
10-Q · filed 2017-08-10
0.45%
10-Q · filed 2017-08-10
2016-03-310.59%
10-Q · filed 2017-05-12